Yonkenafil HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529527

CAS#: 804519-64-0

Description: Yonkenafil HCl is a PDE5 inhibitor potentially for the treatment of erectile dysfunction.

Price and Availability




Yonkenafil HCl is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 529527
Name: Yonkenafil HCl
CAS#: 804519-64-0
Chemical Formula: C24H34ClN5O4S
Exact Mass:
Molecular Weight: 524.07
Elemental Analysis: C, 55.00; H, 6.54; Cl, 6.76; N, 13.36; O, 12.21; S, 6.12

Related CAS #: 804519-64-0 (HCl)   804518-63-6 (free base)  

Synonym: Yonkenafil HCl; Yonkenafil hydrochloride

IUPAC/Chemical Name: 2-(2-ethoxy-5-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-7-propyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one hydrochloride


InChi Code: InChI=1S/C24H33N5O4S.ClH/c1-5-10-28-16-17(4)21-23(28)25-22(26-24(21)30)19-15-18(8-9-20(19)33-7-3)34(31,32)29-13-11-27(6-2)12-14-29;/h8-9,15-16H,5-7,10-14H2,1-4H3,(H,25,26,30);1H


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Zhao S, Yang J, Wang L, Peng S, Yin J, Jia L, Yang X, Yuan Z, Wu C. NF-κB Upregulates Type 5 Phosphodiesterase in N9 Microglial Cells: Inhibition by Sildenafil and Yonkenafil. Mol Neurobiol. 2016 May;53(4):2647-58. doi: 10.1007/s12035-015-9293-0. PubMed PMID: 26108184.

2: Sun H, Wang J, Sun Y, Peng W, Sun L, Yang Y, Gu J. Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma. J Sep Sci. 2016 Oct;39(19):3700-3708. doi: 10.1002/jssc.201600445. PubMed PMID: 27601197.

3: Chen X, Wang N, Liu Y, Liu Y, Zhang T, Zhu L, Wang Y, Wu C, Yang J. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77. doi: 10.1016/j.expneurol.2014.07.007. PubMed PMID: 25064698.

4: Zhu L, Yang JY, Xue X, Dong YX, Liu Y, Miao FR, Wang YF, Xue H, Wu CF. A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model. Mech Ageing Dev. 2015 Sep;150:34-45. doi: 10.1016/j.mad.2015.07.002. PubMed PMID: 26200391.

5: Wang J, Jiang Y, Wang Y, Tang Y, Teng G, Fawcett JP, Kong J, Gu J. A rapid and sensitive LC-MS/MS assay to quantify yonkenafil in rat plasma with application to preclinical pharmacokinetics studies. J Pharm Biomed Anal. 2008 Aug 5;47(4-5):985-9. doi: 10.1016/j.jpba.2008.04.004. PubMed PMID: 18499386.

6: Jing YR, Zhou W, Li WL, Zhao LX, Wang YF. The synthesis of novel taxoids for oral administration. Bioorg Med Chem. 2014 Jan 1;22(1):194-203. doi: 10.1016/j.bmc.2013.11.037. PubMed PMID: 24332858.